Table of Contents 1. Research Methodology 2. Psoriasis - An Overview 2.1. Symptoms of Psoriasis 2.2. Types of Psoriasis 2.3. Causes of Psoriasis 2.4. Triggers, Risk Factors and Complications of Psoriasis 3. Diagnosis of Psoriasis 4. Treatment of Psoriasis 5. Anti-Psoriasis Pipeline Drugs 5.1. Anti-Psoriasis Pipeline Drugs – Cimzia (Certolizumab Pegol) 5.1.1. Description 5.1.2. Regulatory Milestones 5.1.3. Advantages & Disadvantages 5.1.4. Product Profile & Launch Date 5.1.5. Clinical Trials and Status 5.1.6. Pivotal Clinical Trials and Results 5.1.7. Cimzia (Certolizumab Pegol) – Global Market Potential 5.1.8. Cimzia (Certolizumab Pegol) – 7Ps Analysis 5.2. Anti-Psoriasis Pipeline Drugs – Tildrakizumab (MK-3222) 5.2.1. Description 5.2.2. Regulatory Milestones 5.2.3. Advantages & Disadvantages 5.2.4. Product Profile & Launch Date 5.2.5. Clinical Trials and Status 5.2.6. Pivotal Clinical Trials and Results 5.2.7. Tildrakizumab (MK-3222)– Global Market Potential 5.2.8. Tildrakizumab (MK-3222)– 7Ps Analysis 5.3. Anti-Psoriasis Pipeline Drugs – Risankizumab (BI 655066) 5.3.1. Description 5.3.2. Regulatory Milestones 5.3.3. Advantages & Disadvantages 5.3.4. Product Profile & Launch Date 5.3.5. Clinical Trials and Status 5.3.6. Pivotal Clinical Trials and Results 5.3.7. Risankizumab (BI 655066)– Global Market Potential 5.3.8. Risankizumab (BI 655066)– 7Ps Analysis 5.4. Anti-Psoriasis Pipeline Drugs – FP187 5.4.1. Description 5.4.2. Regulatory Milestones 5.4.3. Advantages & Disadvantages 5.4.4. Product Profile & Launch Date 5.4.5. Clinical Trials and Status 5.4.6. Pivotal Clinical Trials and Results 5.4.7. FP187 – Global Market Potential 5.4.8. FP187 – 7Ps Analysis 5.5. Anti-Psoriasis Pipeline Drugs – Skilarence (LAS41008) 5.5.1. Description 5.5.2. Regulatory Milestones 5.5.3. Advantages & Disadvantages 5.5.4. Product Profile & Launch Date 5.5.5. Clinical Trials and Status 5.5.6. Pivotal Clinical Trials and Results 5.5.7. Skilarence (LAS41008) – Global Market Potential 5.5.8. Skilarence (LAS41008) – 7Ps Analysis 5.6. Anti-Psoriasis Pipeline Drugs – Duobrii (IDB 118) 5.6.1. Description 5.6.2. Regulatory Milestones 5.6.3. Advantages & Disadvantages 5.6.4. Product Profile & Launch Date 5.6.5. Clinical Trials and Status 5.6.6. Pivotal Clinical Trials and Results 5.6.7. Duobrii (IDB 118) – Global Market Potential 5.6.8. Duobrii (IDB 118) – 7Ps Analysis 6. Company Profiles 6.1. UCB 6.2. Sun Pharmaceutical Industries Ltd 6.3. Boehringer Ingelheim 6.4. Forward Pharma 6.5. Almirall 6.6. Valeant Pharmaceuticals 7. Number of Psoriasis Patients By Country 7.1. U.S 7.2. U.K 7.3. France 7.4. Italy 7.5. Germany 7.6. Norway

List of Figures Figure 1: Response rate of patients who achieved PASI at week 16 in CIMPASI-1 & CIMPASI-2 Figure 2: Rate of patients achieving at least a two-point improvement to a final score of clearance or almost clear skin on PGA Scale at week 16 in CIMPASI-1 & CIMPASI-2 Figure 3: Response rate of patients who achieved PASI 75 at week 12 in CIMPACT Figure 4: Response rate of patients who achieved PASI 75 at week 16 in CIMPACT Figure 5: Response Rate of patients achieving at least a two-point improvement to a final score of clearance or almost clear skin on PGA Scale at week 16 in CIMPACT Figure 6: Global Cimzia Market Size, By Value, Forecast, 2019-2023 (USD million) Figure 7: Response rate of patients in 100mg dose regimen Figure 8: Response rate of patients in 200mg dose regimen Figure 9: Global Tildrakizumab (MK-3222) Market Size, By Value, Forecast, 2019-2023 (USD million) Figure 10: Response rate of patients in ultiMMa-1 (at wee 16) Figure 11: Response rate of patients in ultiMMa-2 (at week 16) Figure 12: Response rate of patients in ultiMMa-1 (at 1 year) Figure 13: Response rate of patients in ultiMMa-2 (at 1 year) Figure 14: Response rate of patients in IMMvent (at week 16) Figure 15: Response rate of patients in IMMhance (at week 16) Figure 16: Global Risankizumab (BI 655066) Market Size, By Value, Forecast, 2019-2023 (USD million) Figure 17: Percent of Patients achieving PASI75 in 500mg dose arm (at week 20) Figure 18: Percent of Patients achieving PASI75 in 750mg dose arm (at week 20) Figure 19: Percent of Patients achieving PASI75 open label up-titration treatment arm, 750mg dose (at week 20) Figure 20: FP-187 Market Size, By Value, Forecast, 2019-2023 (USD million) Figure 21: Response rate of patients achieving PASI 75 at week 16 Figure 22: Global Skilarence (LAS41008) Market Size, By Value, Forecast, 2021-2023 (USD million) Figure 23: Percentage of success (IGA 0/1) at week 8 Figure 24: Global IDP-118 Market Size, By Value, Forecast, 2019-2023 (USD million) Figure 25: UCB Company Revenues, By Value, in million USD Figure 26: UCB net sales, by value, in million USD Figure 27: UCB net sales by geography, by value, in million USD Figure 28: UCB net sales in 2016, by geography Figure 29: Number of Psoriasis Patients in U.S, 2012-2016 (in million) Figure 30: Number of Psoriasis Patients in U.K, 2012-2016 (in million) Figure 31: Number of Psoriasis Patients in France, 2012-2016 (in million) Figure 32: Number of Psoriasis Patients in Italy, 2012-2016 (in million) Figure 33: Number of Psoriasis Patients in Germany, 2012-2016 (in million) Figure 34: Number of Psoriasis Patients in Norway, 2012-2016 (in million)